Theresa Wardell, PhD Oxford BioMedica

Theresa Wardell is Head of CMC Operations at Oxford BioMedica (OXB). Theresa has over 16 years of experience in the field of Lentiviral Vector clinical and commercial development gained at OXB working in various roles. This includes over 10 years of experience of authoring and reviewing CMC documentation and supporting OXB and strategic partners with applications for clinical trials and product approval.

Theresa holds a Bachelor of Science degree in Genetics and a PhD in inherited & acquired human mitochondrial DNA mutations from The University of Newcastle Upon Tyne.

Before joining OXB, Theresa conducted post-doctoral research into developing an antigenomic therapy for human mitochondrial DNA deletions.